source
- Rapport Therapeutics reports Phase 2 success for RAP-219 in bipolar mania trialRapport Therapeutics announced that its lead candidate RAP-219 met the primary endpoint in a Phase 2 study of adults with acute bipolar mania. The double-blind trial enrolled 253 patients and meas…
- Biopharma Sentiment Index climbs to upbeat 105 in Q3 2026, marking strongest optimism in yearsEndpoints Signal released its Q3 2026 Biopharma Sentiment Index, showing a dramatic lift in industry mood. The survey indicates the sector is finally in a positive territory after a four-year downt…